Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Dabigatran etexilate mesylate

CAS No.

872728-81-9

Innovator/marketer

Pradaxa

Polymorphic form

Form I

Therapeutic Area

Blood & blood forming organs

Status

Pipeline

EU DMF readiness

US DMF readiness

027620

Other documentation

Chinese DMF - under registration

Drug description:

Dabigatran etexilate mesylate is an anticoagulant.
It is indicated for a primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. It is indicated in a prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. It is used in a treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
It is formulated as capsule for oral administration.

 

Mechanism of action:

Dabigatran etexilate is a direct thrombin inhibitor and is the main active principle in plasma. Thrombin enables the conversion of fibrinogen into fibrin during the coagulation cascade. Inhibition of thrombin prevents the development of thrombus. Dabigatran also inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK